SPDR S&P Biotech ETF (XBI) — ()
Key Metrics
News
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: by:
Sentiment: Neutral ()
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly …
Read More
Surprise Breakthrough: US-China Talks Spark Market Rally
Published: by:
Sentiment: Positive ()
An unexpected thaw in US-China trade relations is sending US equity markets soaring this morning.
Read More
Trade Tracker: Joe Terranova sells the XBI, buys Amgen
Published: by:
Sentiment: Neutral ()
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Read More
About SPDR S&P Biotech ETF XBI
The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select IndustryTM Index (the “Index”)Seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the following sub-industries: BiotechnologySeeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocksAllows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing